In a Healthcare summit hosted by Forbes on Thursday, Martin Shkreli, the founder and CEO of Turing Pharmaceuticals, admitted he made a mistake by raising the price of a decades-old drug by more than 5,000 percent. But it’s not the mistake you might expect.

In response to an audience member who asked him if he would have done anything differently in regard to raising the price of the drug, Daraprim, Shkreli replied, “I probably would have raised the price higher.”

That price hike, which brought a pill of Daraprim from $13.50 to $750 earlier this year, has drawn fiery scorn from the public, media, and lawmakers. Daraprim is a 62-year old drug used to treat toxoplasmosis, a disease caused by a parasitic infection. Toxoplasmosis often strikes people with compromised immune systems, such as AIDS patients.

During the 25-minute interview, Shkreli explained the price hike regret. “I could have raised it higher and made more profits for our shareholders, which is my primary duty,” he said.

According to Forbes, Shkreli went on to explain why he recently decided to go back on a plan to lower Daraprim’s price, saying that companies were still “begging” for business despite the higher drug cost. He also blamed complicated distribution models and a lack of alternatives for forcing the price hike.

Earlier this week, a pharmaceutical drug manager announced that it would promote the distribution of a $1-per-pill alternative to Daraprim.